Go to main content
A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients
Khan, Lubna; Elstrott, Ben; Olyaei, Ali; Lockridge, Joseph; Scott, David
2020
Download
Formats
Format
BibTeX
MARCXML
TextMARC
MARC
DublinCore
EndNote
NLM
RefWorks
RIS
Add to Basket

Files

Abstract

There are few studies that compare the safety of multiple induction therapies in simultaneous pancreas-kidney transplant (SPKT) patients. The purpose of this study is to compare basiliximab, thymoglobulin (ATG), and alemtuzumab according to HLA matching to assess allograft survival, rejection rate, and post-operative complications.

Details

Title
A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients
Creator
Khan, Lubna : Oregon Health and Science University
Elstrott, Ben : Oregon Health and Science University
Olyaei, Ali : Oregon Health and Science University
Lockridge, Joseph : Oregon Health and Science University
Scott, David : Oregon Health and Science University
Meeting Name
Research Week, Oregon Health and Science University, 2020
Publisher
Oregon Health and Science University
Date
2020
Subjects
Keywords
DOI
https://doi.org/10.6083/9p290b031
Language
English
Content Type
Abstract
Copyright Status
In copyright - joint owners
Usage Statement
Record ID
8271
Record Created
2023-06-29
Record Appears in
OHSU Works > Events > Research Week
All Records

PDF

Statistics

from
to
Export
Download Full History